Tetraphase Pharmaceuticals’ Xerava (eravacycline) Receives FDA’s Approval for Complicated Intra-Abdominal Infections (CIAI)

 Tetraphase Pharmaceuticals’ Xerava (eravacycline) Receives FDA’s Approval for Complicated Intra-Abdominal Infections (CIAI)

Tetraphase Pharmaceuticals’ Xerava (eravacycline) Receives FDA’s Approval for Complicated Intra-Abdominal Infections (CIAI)

Shots:

  • The approval is based on the two P-III IGNITE study assessing Xerava (eravacycline, bid, IV) vs ertapenem & meropenem in patients with cIAI
  • The study demonstrated a non-inferiority data clinical response vs ertapenem with well-tolerated results and achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates
  • Xerava (eravacyclin, IV) is a novel fully-synthetic fluorocycline, has also received CHMP approval for CIAI in H1’18 and will be available in Q4’18

Click here to read full press release/ article | Ref: TetraPhase | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post